WO2006061336A3 - Oral compositions for absorption of phosphorus compounds - Google Patents

Oral compositions for absorption of phosphorus compounds Download PDF

Info

Publication number
WO2006061336A3
WO2006061336A3 PCT/EP2005/056289 EP2005056289W WO2006061336A3 WO 2006061336 A3 WO2006061336 A3 WO 2006061336A3 EP 2005056289 W EP2005056289 W EP 2005056289W WO 2006061336 A3 WO2006061336 A3 WO 2006061336A3
Authority
WO
WIPO (PCT)
Prior art keywords
phosphorus compounds
absorption
oral compositions
present
hyperphosphatemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/056289
Other languages
French (fr)
Other versions
WO2006061336A2 (en
Inventor
Vincenzo Savica
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36035790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006061336(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to SI200531182T priority Critical patent/SI1827386T1/en
Priority to PL05810997T priority patent/PL1827386T3/en
Priority to AT05810997T priority patent/ATE481091T1/en
Priority to DK05810997.6T priority patent/DK1827386T3/en
Priority to BRPI0518517-3A priority patent/BRPI0518517A2/en
Priority to HR20100653T priority patent/HRP20100653T1/en
Priority to EP05810997A priority patent/EP1827386B1/en
Priority to DE602005023648T priority patent/DE602005023648D1/en
Priority to JP2007544881A priority patent/JP5049135B2/en
Application filed by Individual filed Critical Individual
Priority to US11/792,047 priority patent/US7815898B2/en
Priority to CA2587924A priority patent/CA2587924C/en
Priority to MX2007006704A priority patent/MX2007006704A/en
Priority to KR1020077012746A priority patent/KR101283820B1/en
Publication of WO2006061336A2 publication Critical patent/WO2006061336A2/en
Publication of WO2006061336A3 publication Critical patent/WO2006061336A3/en
Anticipated expiration legal-status Critical
Priority to US12/861,539 priority patent/US20100316578A1/en
Priority to US12/883,498 priority patent/US8518379B2/en
Priority to US14/462,038 priority patent/US20140356297A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides medicaments useful for reducing phosphorus serum level, especially in those subjects affected from hyperphosphatemia. More specifically, the present invention relates to pharmaceutical compositions to be administered by oral route in fasting periods, in order to absorb phosphorus compounds from fluids of the enteric tract, especially from saliva.
PCT/EP2005/056289 2004-12-07 2005-11-29 Oral compositions for absorption of phosphorus compounds Ceased WO2006061336A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
KR1020077012746A KR101283820B1 (en) 2004-12-07 2005-11-29 Oral compositions for absorption of phosphorus compounds
US11/792,047 US7815898B2 (en) 2004-12-07 2005-11-29 Oral compositions for absorption of phosphorus compounds
AT05810997T ATE481091T1 (en) 2004-12-07 2005-11-29 ORAL COMPOSITIONS FOR ABSORPTION OF PHOSPHORUS COMPOUNDS
DK05810997.6T DK1827386T3 (en) 2004-12-07 2005-11-29 Oral compositions for absorption of phosphorus compounds
BRPI0518517-3A BRPI0518517A2 (en) 2004-12-07 2005-11-29 oral compositions for absorption of phosphorus compounds
HR20100653T HRP20100653T1 (en) 2004-12-07 2005-11-29 ORAL MIXTURES FOR THE ABSORPTION OF PHOSPHORUS COMPOUNDS
EP05810997A EP1827386B1 (en) 2004-12-07 2005-11-29 Oral compositions for absorption of phosphorus compounds
DE602005023648T DE602005023648D1 (en) 2004-12-07 2005-11-29 ORAL COMPOSITIONS FOR ABSORPTION OF PHOSPHORUS COMPOUNDS
JP2007544881A JP5049135B2 (en) 2004-12-07 2005-11-29 Oral composition for absorption of phosphorus compounds
SI200531182T SI1827386T1 (en) 2004-12-07 2005-11-29 Oral compositions for absorption of phosphorus compounds
MX2007006704A MX2007006704A (en) 2004-12-07 2005-11-29 Oral compositions for absorption of phosphorus compounds.
PL05810997T PL1827386T3 (en) 2004-12-07 2005-11-29 Oral compositions for absorption of phosphorus compounds
CA2587924A CA2587924C (en) 2004-12-07 2005-11-29 Oral compositions for absorption of phosphorus compounds
US12/861,539 US20100316578A1 (en) 2004-12-07 2010-08-23 Oral compositions for absorption of phosphorous compounds
US12/883,498 US8518379B2 (en) 2004-12-07 2010-09-16 Oral compositions for absorption of phosphorous compounds
US14/462,038 US20140356297A1 (en) 2004-12-07 2014-08-18 Oral compositions for absorption of phosphorous compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000015A ITME20040015A1 (en) 2004-12-07 2004-12-07 CHEWING GUM, RUBBER CANDIES, TABLETS, SLOW TABLETS OF CHELANTI PHOSPHATE AND / OR PHOSPHORUS SALIVAR AND CAPSULES WITH SLOW RELEASE OF CHELANTS PHOSPHATE AND / OR PHOSPHORUS AT GASTROENTERIC LEVEL.
ITME2004A000015 2004-12-07

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US11/792,047 A-371-Of-International US7815898B2 (en) 2004-12-07 2005-11-29 Oral compositions for absorption of phosphorus compounds
US12/861,539 Division US20100316578A1 (en) 2004-12-07 2010-08-23 Oral compositions for absorption of phosphorous compounds
US12/883,498 Division US8518379B2 (en) 2004-12-07 2010-09-16 Oral compositions for absorption of phosphorous compounds

Publications (2)

Publication Number Publication Date
WO2006061336A2 WO2006061336A2 (en) 2006-06-15
WO2006061336A3 true WO2006061336A3 (en) 2006-09-14

Family

ID=36035790

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/056289 Ceased WO2006061336A2 (en) 2004-12-07 2005-11-29 Oral compositions for absorption of phosphorus compounds

Country Status (21)

Country Link
US (4) US7815898B2 (en)
EP (1) EP1827386B1 (en)
JP (1) JP5049135B2 (en)
KR (1) KR101283820B1 (en)
CN (1) CN101068535A (en)
AT (1) ATE481091T1 (en)
BR (1) BRPI0518517A2 (en)
CA (1) CA2587924C (en)
CY (1) CY1110985T1 (en)
DE (1) DE602005023648D1 (en)
DK (1) DK1827386T3 (en)
ES (1) ES2352957T3 (en)
HR (1) HRP20100653T1 (en)
IT (1) ITME20040015A1 (en)
MX (1) MX2007006704A (en)
PL (1) PL1827386T3 (en)
PT (1) PT1827386E (en)
RS (1) RS51507B (en)
RU (1) RU2392926C2 (en)
SI (1) SI1827386T1 (en)
WO (1) WO2006061336A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986669B2 (en) 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
US10149895B2 (en) 2013-06-27 2018-12-11 Virbac Composition for the treatment of progressive renal diseases

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITME20040015A1 (en) * 2004-12-07 2005-03-07 Vincenzo Savica CHEWING GUM, RUBBER CANDIES, TABLETS, SLOW TABLETS OF CHELANTI PHOSPHATE AND / OR PHOSPHORUS SALIVAR AND CAPSULES WITH SLOW RELEASE OF CHELANTS PHOSPHATE AND / OR PHOSPHORUS AT GASTROENTERIC LEVEL.
ITRM20060204A1 (en) * 2006-04-10 2007-10-11 Vincenzo Savica PHARMACEUTICALS AND PHARMACEUTICALS FOR HYPERPROTIC HYPROPROSTICAL NORMOPROTEIC DIETS ALL HYPOPHOSPHORIC AND HYPOFOSPHORIC DRINKS
WO2008005217A2 (en) * 2006-07-05 2008-01-10 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
WO2009126145A1 (en) * 2008-04-08 2009-10-15 Cypress Pharmaceutical, Inc. Phosphate-binding chitosan and uses thereof
US7943597B2 (en) * 2008-04-08 2011-05-17 Cypress Pharmaceutical, Inc. Phosphate-binding chitosan and uses thereof
US8877907B2 (en) 2010-06-07 2014-11-04 The Johns Hopkins University Molecularly imprinted polymers
US9314523B2 (en) 2010-09-21 2016-04-19 Elwha Llc Ingestible salt grabber
EP2441436A1 (en) * 2010-10-13 2012-04-18 Fresenius Medical Care Deutschland GmbH Easy to administer phosphate binder formulation
WO2012098562A2 (en) 2011-01-19 2012-07-26 Panacea Biotec Limited Liquid oral compositions of lanthanum salts
WO2012143011A1 (en) 2011-04-20 2012-10-26 Gumlink A/S Chewing gum comprising chitosan for use in reduction of the level of free phosphorus compounds in the digestive juice
WO2012143008A1 (en) 2011-04-20 2012-10-26 Gumlink A/S Reduction of the level of free phosphorus compounds in the digestive juice
LT2717896T (en) * 2011-06-08 2017-02-27 Kai Pharmaceuticals, Inc. Therapeutic agents for regulating serum phosphorus
CN104703486A (en) * 2012-09-04 2015-06-10 德克萨斯大学系统董事会 Citrate-rich calcium-magnesium supplement and uses thereof
WO2014166545A1 (en) 2013-04-12 2014-10-16 Cm&D Pharma Ltd Compositions comprising a mixture of elastomers and chitosan and use thereof for treating disorders of phosphorous mineral metabolism
LT3003327T (en) 2013-06-05 2017-12-27 Tricida Inc. Proton-binding polymers for oral administration
CN103536977A (en) * 2013-11-04 2014-01-29 于杰 Hemoperfusion apparatus
US9744128B2 (en) 2014-06-05 2017-08-29 Mastix LLC Method for manufacturing medicated chewing gum without cooling
CN113855703B (en) * 2014-12-10 2025-11-25 特里赛达公司 Proton-binding polymers for oral administration
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
US10765658B2 (en) 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids
AU2018360867B2 (en) 2017-11-03 2024-12-12 Tricida, Inc. Compositions for and method of treating acid-base disorders
US20200383926A1 (en) * 2017-11-29 2020-12-10 Shin Era Technology Co. Ltd. Enteric coated pharmaceutical composition and use thereof
US11273123B2 (en) 2018-07-18 2022-03-15 USpharma Ltd Chewable pharmaceutical dosage forms
US12390416B2 (en) 2018-07-18 2025-08-19 USpharma Ltd Chewable pharmaceutical dosage forms
CN109528764B (en) * 2018-09-30 2021-04-06 北京市中关村医院 Gel-based layered inorganic phosphorus binding agent and preparation method and application thereof

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163777A (en) * 1977-04-29 1979-08-07 Lewis/Howe Company Controlled antacid delivery form and method of treatment therewith
JPS62132830A (en) * 1985-12-05 1987-06-16 Teijin Ltd Slow-releasing medicinal drug composition
US4814176A (en) * 1985-01-11 1989-03-21 Teijin Ltd. Sustained release preparation
EP0426098A1 (en) * 1989-11-01 1991-05-08 Bartz, Volker Phosphate binding agent for oral administration
JPH05213762A (en) * 1992-01-31 1993-08-24 Suzuyo Kk Phosphorus adsorbent
US5496545A (en) * 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
EP0793960A1 (en) * 1996-03-05 1997-09-10 Mitsubishi Chemical Corporation Use of anion exchange resins for the manufacture of a medicament for the treatment of hyperphosphatemia
US5968976A (en) * 1995-03-25 1999-10-19 Anormed Inc. Pharmaceutical composition containing selected lanthanum carbonate hydrates
EP1046410A2 (en) * 1999-04-20 2000-10-25 Vitasyn GmbH Calcium and magnesium containing phosphate binding agent for the treatment of hyperphosphatemia
WO2002051259A1 (en) * 2000-12-22 2002-07-04 Wm. Wrigley Jr. Company Coated chewing gum products containing various antacids
US20030138518A1 (en) * 2002-01-16 2003-07-24 Kiefer Jesse John Center-filled chewing gum containing a deliverable form of calcium
WO2005018651A1 (en) * 2003-08-26 2005-03-03 Shire Holdings Ag Pharmaceutical formulation comprising lanthanum compounds
WO2005041902A2 (en) * 2003-11-03 2005-05-12 Ilypsa, Inc. Anion-binding polymers and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3818807A (en) * 1972-12-06 1974-06-25 Eng Concrete Placer Inc Slurry pump piston seal
US4181718A (en) * 1975-12-29 1980-01-01 Mason Norbert S Polyanion-stabilized aluminum hydrogels
US4163177A (en) * 1977-10-17 1979-07-31 Ward Derrick A Oscillation generator providing oscillations of varying amplitude
US4160820A (en) * 1977-11-28 1979-07-10 General Mills, Inc. Plaque inhibiting composition and method
US4515769A (en) * 1981-12-01 1985-05-07 Borden, Inc. Encapsulated flavorant material, method for its preparation, and food and other compositions incorporating same
US4386106A (en) * 1981-12-01 1983-05-31 Borden, Inc. Process for preparing a time delayed release flavorant and an improved flavored chewing gum composition
US4512968A (en) * 1982-11-30 1985-04-23 Lion Corporation Oral compositions
JPS61161216A (en) * 1985-01-11 1986-07-21 Teijin Ltd Sustained release drug composition using chitosan
JPS63310833A (en) * 1987-06-10 1988-12-19 Nippon Medical Supply Corp Phosphorus adsorbing capsule agent
US5030459A (en) * 1989-11-07 1991-07-09 Warner-Lambert Company High impact mint flavor for high base chewing gum
IE980990A1 (en) * 1998-11-27 2000-05-31 Fuisz Internat Ltd Composition and Method for Medicated Chewing Gum Delivery System
FI121528B (en) * 2000-10-30 2010-12-31 Biohit Oyj A pharmaceutical composition for reducing the risk of cancer by topically binding acetaldehyde in saliva, stomach or colon
US20030072841A1 (en) * 2001-03-19 2003-04-17 The Procter & Gamble Campany Polybutene containing chewing gum and confection
ITMI20012320A1 (en) * 2001-11-06 2003-05-06 Perfetti Van Melle Spa ORAL COMPOSITIONS SOLID ANTI-TARTAR AND ANTI-BACTERIAL PLATE, USEFUL AS ADJUVANTS IN DENTISTRY-STOMATOLOGICAL HYGIENE
IL162823A0 (en) * 2002-01-03 2005-11-20 Yissum Res Dev Co Edible compositions capable of removing oral biofilm
SE0302947D0 (en) * 2003-01-24 2003-11-07 Magle Ab A composition material for transmucosal delivery
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
ITME20040015A1 (en) * 2004-12-07 2005-03-07 Vincenzo Savica CHEWING GUM, RUBBER CANDIES, TABLETS, SLOW TABLETS OF CHELANTI PHOSPHATE AND / OR PHOSPHORUS SALIVAR AND CAPSULES WITH SLOW RELEASE OF CHELANTS PHOSPHATE AND / OR PHOSPHORUS AT GASTROENTERIC LEVEL.
US8323683B2 (en) * 2005-05-18 2012-12-04 Mcneil-Ppc, Inc. Flavoring of drug-containing chewing gums
US20070207206A1 (en) * 2006-03-02 2007-09-06 Rice Bronwyn C Chewable pain formula

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163777A (en) * 1977-04-29 1979-08-07 Lewis/Howe Company Controlled antacid delivery form and method of treatment therewith
US4814176A (en) * 1985-01-11 1989-03-21 Teijin Ltd. Sustained release preparation
JPS62132830A (en) * 1985-12-05 1987-06-16 Teijin Ltd Slow-releasing medicinal drug composition
EP0426098A1 (en) * 1989-11-01 1991-05-08 Bartz, Volker Phosphate binding agent for oral administration
JPH05213762A (en) * 1992-01-31 1993-08-24 Suzuyo Kk Phosphorus adsorbent
US5496545A (en) * 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5968976A (en) * 1995-03-25 1999-10-19 Anormed Inc. Pharmaceutical composition containing selected lanthanum carbonate hydrates
EP0793960A1 (en) * 1996-03-05 1997-09-10 Mitsubishi Chemical Corporation Use of anion exchange resins for the manufacture of a medicament for the treatment of hyperphosphatemia
EP1046410A2 (en) * 1999-04-20 2000-10-25 Vitasyn GmbH Calcium and magnesium containing phosphate binding agent for the treatment of hyperphosphatemia
WO2002051259A1 (en) * 2000-12-22 2002-07-04 Wm. Wrigley Jr. Company Coated chewing gum products containing various antacids
US20030138518A1 (en) * 2002-01-16 2003-07-24 Kiefer Jesse John Center-filled chewing gum containing a deliverable form of calcium
WO2005018651A1 (en) * 2003-08-26 2005-03-03 Shire Holdings Ag Pharmaceutical formulation comprising lanthanum compounds
WO2005041902A2 (en) * 2003-11-03 2005-05-12 Ilypsa, Inc. Anion-binding polymers and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Fosrenol (R) approved to reduce phosphorus levels in end-stage renal disease patients", SHIRE PHARMACEUTICALS GROUP PLC, 27 November 2004 (2004-11-27), XP002376456, Retrieved from the Internet <URL:http://www.newswise.com/articles/view/507957/> [retrieved on 20060410] *
PATENT ABSTRACTS OF JAPAN vol. 011, no. 361 (C - 459) 25 November 1987 (1987-11-25) *
PATENT ABSTRACTS OF JAPAN vol. 017, no. 659 (C - 1137) 7 December 1993 (1993-12-07) *
SCHILLER L R ET AL: "EFFECT OF THE TIME OF ADMINISTRATION OF CALCIUM ACETATE ON PHOSPHORUS BINDING", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 320, 27 April 1989 (1989-04-27), pages 1110 - 1113, XP008059941, ISSN: 1533-4406 *
SMITH, D.R., CHANG, B.S., AND JOHNSON, C.E.: "Aluminum hydroxide: Evaluation of two dosage forms and two dosing schedules inreducing intestinal phosphate absorption", AMERICAN JOURNAL OF HOSPITAL PHARMACY, vol. 35, January 1978 (1978-01-01), pages 58 - 61, XP008062881 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986669B2 (en) 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
US10149895B2 (en) 2013-06-27 2018-12-11 Virbac Composition for the treatment of progressive renal diseases

Also Published As

Publication number Publication date
PT1827386E (en) 2010-12-03
US20110002858A1 (en) 2011-01-06
CA2587924C (en) 2013-08-20
DK1827386T3 (en) 2011-07-11
US20100316578A1 (en) 2010-12-16
RU2392926C2 (en) 2010-06-27
WO2006061336A2 (en) 2006-06-15
HRP20100653T1 (en) 2011-01-31
MX2007006704A (en) 2008-01-16
US20080125394A1 (en) 2008-05-29
US8518379B2 (en) 2013-08-27
US7815898B2 (en) 2010-10-19
JP5049135B2 (en) 2012-10-17
EP1827386A2 (en) 2007-09-05
RS51507B (en) 2011-06-30
CN101068535A (en) 2007-11-07
CY1110985T1 (en) 2015-06-11
ES2352957T3 (en) 2011-02-24
ATE481091T1 (en) 2010-10-15
KR101283820B1 (en) 2013-07-15
ITME20040015A1 (en) 2005-03-07
BRPI0518517A2 (en) 2008-11-25
EP1827386B1 (en) 2010-09-15
DE602005023648D1 (en) 2010-10-28
JP2008523022A (en) 2008-07-03
SI1827386T1 (en) 2011-01-31
US20140356297A1 (en) 2014-12-04
CA2587924A1 (en) 2006-06-15
PL1827386T3 (en) 2011-05-31
KR20070090904A (en) 2007-09-06
RU2007125702A (en) 2009-01-20

Similar Documents

Publication Publication Date Title
CY1110985T1 (en) ORAL COMPOSITIONS FOR ABSORPTION OF PHOSPHORUS COMPOUNDS
EP1976558A4 (en) USE OF AN IMMUNOGENIC COMPOSITION OF PCV2 FOR THE REDUCTION OF CLINICAL SYMPTOMS
EP2011482A4 (en) SOLID PREPARATION FOR ORAL APPLICATION
IL177283A (en) Pyrazolopyrimidine compounds, use thereof for the preparation of medicaments and pharmaceutical compositions comprising same
IL210756A0 (en) Carbostyril compound, process for their preparation and pharmaceutical compositions containing them
WO2008128049A3 (en) Tetrahydrobiopterin compositions and methods of measuring
IL192740A (en) Use of acid spingomyelinase-containing compositions for the preparation of medicaments formulated for intraventricular administration for treating niemann-pick a or b disease
NO20075111L (en) Pharmaceutical composition
EA018193B3 (en) Compounds and pharmaceutical compositions for reducing uric acid level
DK2254549T4 (en) AURAL PHARMACEUTICAL COMPOSITIONS, CONTAINING BORATE-POLYOL COMPLEXES
EP1615664A4 (en) Pharmaceutical composition for treatment of immunological disorders
IL188980A0 (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily
IL183930A0 (en) Use of cladribine for preparation of pharmaceutical compositions
EP1815852A4 (en) NONAQUEOUS PREPARATION FOR PERCUTANEOUS ABSORPTION CONTAINING NON-STEROID ANTI-INFLAMMATORY ANALGESIC
WO2008106689A3 (en) Breakthrough pain management
WO2007131070A3 (en) Compositions, dosage forms and methods of treating emesis
WO2006017726A3 (en) Polysulfated glycosides and salts thereof
WO2007067875A3 (en) Pyridinyl sulfonamide modulators of chemokine receptors
WO2005107773A3 (en) Solid dosage form of wetted heparin
WO2008060546A3 (en) Oral formulations
WO2007075794A3 (en) Oral formulations comprising tigecycline
EP1846000A4 (en) Pharmaceutical compositions containing bisphosphonate for improving oral absorption
WO2008033930A3 (en) Vinca derivatives
WO2007139833A3 (en) Imidazoazephinone compounds
WO2008116215A3 (en) Phosphorus binder for treatment of renal disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2587924

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11792047

Country of ref document: US

Ref document number: 200580041458.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/006704

Country of ref document: MX

Ref document number: 1020077012746

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007544881

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2151/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005810997

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007125702

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005810997

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11792047

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0518517

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: P-2010/0513

Country of ref document: RS